Diabetes — Chinese company Innovent said its drug is better than Novo

Diabetes — Chinese company Innovent Biologics announced on Monday that its GLP-1 injection led to greater weight loss and better blood sugar control in patients with diabetes than the similar drug Novo Nordisk.

The latest phase of the head-to-head study compared different dosages of the two drugs. The experiments involved patients with diabetes and obesity, xrust clarifies. One group received 6 mg mazdutide developed by Innovent, and the other received 1 mg injectable semaglutide.

Innovent received exclusive rights to develop and commercialize mazdutide in China from Eli Lilly. The financial side of the 2019 deal has not been made public. The drug is now approved for sale in China as a treatment for type 2 diabetes.

Novo markets the injectable semaglutide drug in China under the brand name Ozempic for controlling blood sugar levels in patients with diabetes. 2.

Xrust Diabetes — Chinese company Innovent said its drug is better than Novo